Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sesen Bio stock | 1.09

Own Sesen Bio stock in just a few minutes.

Posted

Fact checked

Sesen Bio, Inc is a biotechnology business based in the US. Sesen Bio shares (SESN) are listed on the NASDAQ and all prices are listed in US Dollars. Sesen Bio employs 25 staff and has a trailing 12-month revenue of around USD$11.2 million.

How to buy shares in Sesen Bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sesen Bio. Find the stock by name or ticker symbol: SESN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sesen Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.09, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sesen Bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sesen Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Sesen Bio's share price?

Since the stock market crash in March caused by coronavirus, Sesen Bio's share price has had significant positive movement.

Its last market close was USD$1.09, which is 21.91% up on its pre-crash value of USD$0.8512 and 194.59% up on the lowest point reached during the March crash when the shares fell as low as USD$0.37.

If you had bought USD$1,000 worth of Sesen Bio shares at the start of February 2020, those shares would have been worth USD$567.88 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,170.78.

Sesen Bio share price

Use our graph to track the performance of SESN stocks over time.

Sesen Bio shares at a glance

Information last updated 2020-11-24.
Latest market close USD$1.09
52-week range USD$0.37 - USD$1.54
50-day moving average USD$1.1453
200-day moving average USD$0.9769
Wall St. target price USD$3.42
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.046

Buy Sesen Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sesen Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sesen Bio price performance over time

Historical closes compared with the close of $1.09 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-30) 6.86%
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Sesen Bio financials

Revenue TTM USD$11.2 million
Gross profit TTM USD$-24,663,000
Return on assets TTM -17.5%
Return on equity TTM 0%
Profit margin 0%
Book value $0.168
Market capitalisation USD$148.7 million

TTM: trailing 12 months

Shorting Sesen Bio shares

There are currently 1.8 million Sesen Bio shares held short by investors – that's known as Sesen Bio's "short interest". This figure is 2.1% up from 1.8 million last month.

There are a few different ways that this level of interest in shorting Sesen Bio shares can be evaluated.

Sesen Bio's "short interest ratio" (SIR)

Sesen Bio's "short interest ratio" (SIR) is the quantity of Sesen Bio shares currently shorted divided by the average quantity of Sesen Bio shares traded daily (recently around 2.2 million). Sesen Bio's SIR currently stands at 0.85. In other words for every 100,000 Sesen Bio shares traded daily on the market, roughly 850 shares are currently held short.

However Sesen Bio's short interest can also be evaluated against the total number of Sesen Bio shares, or, against the total number of tradable Sesen Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sesen Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sesen Bio shares in existence, roughly 10 shares are currently held short) or 0.0143% of the tradable shares (for every 100,000 tradable Sesen Bio shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sesen Bio.

Find out more about how you can short Sesen Bio stock.

Sesen Bio share dividends

We're not expecting Sesen Bio to pay a dividend over the next 12 months.

Sesen Bio share price volatility

Over the last 12 months, Sesen Bio's shares have ranged in value from as little as $0.37 up to $1.54. A popular way to gauge a stock's volatility is its "beta".

SESN.US volatility(beta: 1.23)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sesen Bio's is 1.2334. This would suggest that Sesen Bio's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Sesen Bio overview

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site